L-carnitine
Orphan DrugFDA Approved, EMA Approved
Description
L-carnitine is an amino acid derivative essential for fatty acid metabolism and energy production in mitochondria. It is used in metabolic disorders affecting mitochondrial function and has orphan designation for primary carnitine deficiency. The drug facilitates transport of long-chain fatty acids into mitochondria for beta-oxidation.
Indications & Therapeutic Use
primary carnitine deficiency, metabolic disorders with mitochondrial dysfunction, fatty acid oxidation disorders
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
L-carnitine
| Generic Name | L-carnitine |
| Brands | 1 brand available |
| Active Ingredient | levocarnitine |
| Drug Class | primary carnitine deficiency |
| Manufacturer | Leadiant Biosciences |
| Dosage Forms | Oral tablets 330mg; oral solution 100mg/mL; IV injection 200mg/mL |
| Medical Code | A16AA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00006250 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes